185 related articles for article (PubMed ID: 32393238)
1. Forecasting drug utilization and expenditure: ten years of experience in Stockholm.
Linnér L; Eriksson I; Persson M; Wettermark B
BMC Health Serv Res; 2020 May; 20(1):410. PubMed ID: 32393238
[TBL] [Abstract][Full Text] [Related]
2. Forecasting drug utilization and expenditure in a metropolitan health region.
Wettermark B; Persson ME; Wilking N; Kalin M; Korkmaz S; Hjemdahl P; Godman B; Petzold M; Gustafsson LL;
BMC Health Serv Res; 2010 May; 10():128. PubMed ID: 20478043
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of annual prescription drug expenditure forecasts in AJHP.
Hartke PL; Vermeulen LC; Hoffman JM; Shah ND; Doloresco F; Suda KJ; Li EC; Matusiak LM; Hunkler RJ; Schumock GT
Am J Health Syst Pharm; 2015 Oct; 72(19):1642-8. PubMed ID: 26386105
[TBL] [Abstract][Full Text] [Related]
4. Forecasting Ontario Oncology Drug Expenditures: A Hybrid Approach to Improving Accuracy.
Murray PM; Shalaby YA; Ieraci L; Borg E; Sniekers D; Esensoy AV; Arias J
Appl Health Econ Health Policy; 2020 Feb; 18(1):127-137. PubMed ID: 31724104
[TBL] [Abstract][Full Text] [Related]
5. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
6. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
Hutchings A; Schey C; Dutton R; Achana F; Antonov K
Orphanet J Rare Dis; 2014 Feb; 9():22. PubMed ID: 24524281
[TBL] [Abstract][Full Text] [Related]
7. Predictors of primary health care pharmaceutical expenditure by districts in Uganda and implications for budget setting and allocation.
Mujasi PN; Puig-Junoy J
BMC Health Serv Res; 2015 Aug; 15():334. PubMed ID: 26290329
[TBL] [Abstract][Full Text] [Related]
8. EU pharmaceutical expenditure forecast.
Urbinati D; Rémuzat C; Kornfeld Å; Vataire AL; Cetinsoy L; Aballéa S; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226837
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical expenditure forecast model to support health policy decision making.
Rémuzat C; Urbinati D; Kornfeld Å; Vataire AL; Cetinsoy L; Aballéa S; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226830
[TBL] [Abstract][Full Text] [Related]
10. Novel methodology for pharmaceutical expenditure forecast.
Vataire AL; Cetinsoy L; Aballéa S; Rémuzat C; Urbinati D; Kornfeld Å; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226843
[TBL] [Abstract][Full Text] [Related]
11. Exponential smoothing method for forecasting drug expenditures.
D'Sa MM; Nakagawa RS; Hill DS; Tan JK
Am J Hosp Pharm; 1994 Oct; 51(20):2581-8. PubMed ID: 7847421
[TBL] [Abstract][Full Text] [Related]
12. National trends in prescription drug expenditures and projections for 2019.
Schumock GT; Stubbings J; Hoffman JM; Wiest MD; Suda KJ; Rim MH; Tadrous M; Tichy EM; Cuellar S; Clark JS; Matusiak LM; Hunkler RJ; Vermeulen LC
Am J Health Syst Pharm; 2019 Jul; 76(15):1105-1121. PubMed ID: 31199861
[TBL] [Abstract][Full Text] [Related]
13. The drug budget silo mentality: the French case.
Le Pen C
Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
[TBL] [Abstract][Full Text] [Related]
14. High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines.
Eriksen J; Gustafsson LL; Ateva K; Bastholm-Rahmner P; Ovesjö ML; Jirlow M; Juhasz-Haverinen M; Lärfars G; Malmström RE; Wettermark B; Andersén-Karlsson E;
BMJ Open; 2017 May; 7(4):e014345. PubMed ID: 28465306
[TBL] [Abstract][Full Text] [Related]
15. An analysis of orphan medicine expenditure in Europe: is it sustainable?
Mestre-Ferrandiz J; Palaska C; Kelly T; Hutchings A; Parnaby A
Orphanet J Rare Dis; 2019 Dec; 14(1):287. PubMed ID: 31829218
[TBL] [Abstract][Full Text] [Related]
16. [Factor associated with medicines utilization and expenditure in Mexico].
Wirtz VJ; Serván-Mori E; Heredia-Pi I; Dreser A; Ávila-Burgos L
Salud Publica Mex; 2013; 55 Suppl 2():S112-22. PubMed ID: 24626686
[TBL] [Abstract][Full Text] [Related]
17. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria.
Kossmeier M; Themanns M; Hatapoglu L; Kogler B; Keuerleber S; Lichtenecker J; Sauermann R; Bucsics A; Freissmuth M; Zebedin-Brandl E
Front Pharmacol; 2021; 12():726758. PubMed ID: 34483937
[No Abstract] [Full Text] [Related]
19. The impact of Medicare part D on income-related inequality in pharmaceutical expenditure.
Carvalho N; Petrie D; Chen L; Salomon JA; Clarke P
Int J Equity Health; 2019 Apr; 18(1):57. PubMed ID: 30992000
[TBL] [Abstract][Full Text] [Related]
20. International health spending forecasts: concepts and evaluation.
Getzen TE; Poullier JP
Soc Sci Med; 1992 May; 34(9):1057-68. PubMed ID: 1631605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
